Corrigendum: Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia (Oncogene (2013) 32 (5359-5368) DOI: 10.1038/onc.2013.40);Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia

Oncogene

Volumn 32, Issue 46, 2013, Pages 5359-5368

  Lee Sherick, A B ^a   Eisenman, K M ^a   Sather, S ^a   McGranahan, A ^b   Armistead, P M ^c   McGary, C S ^c   Hunsucker, S A ^c   Schlegel, J ^a   Martinson, H ^b   Cannon, C ^a   Keating, A K ^a   Earp, H S ^c   Liang, X ^b   Deryckere, D ^a   Graham, D K ^a  

^a Nutrition Obesity Research Center at the University of Colorado   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

acute leukemia; pediatric; targeted therapy; tyrosine kinase

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 1; IMMUNOGLOBULIN G1; MER RECEPTOR TYROSINE KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; SHORT HAIRPIN RNA; STAT6 PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MONOCYTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; APOPTOSIS; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CELL SURFACE; COLONY FORMATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LEUKEMOGENESIS; MOUSE; MYELOBLAST; MYELOID PROGENITOR CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

MUS;

EID: 84888000018     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2016.295     Document Type: Erratum

References (35)

1. Pulte D, Gondos A, Brenner H. Expected long-term survival of patients diagnosed with acute myeloblastic leukemia during 2006-2010. Ann Oncol 2010; 21: 335-341.
2. Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. official journal of the American Society of Clinical Oncology 2011; 29: 551-565.
3. Pfirrmann M, Ehninger G, Thiede C, Bornhauser M, Kramer M, Rollig C et al. Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial. Lancet Oncol 2012; 13: 207-214.
4. Sander A, Zimmermann M, Dworzak M, Fleischhack G, von Neuhoff C, Reinhardt D et al. Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials. Leukemia 2010; 24: 1422-1428.
5. Trifilio SM, Rademaker AW, Newman D, Coyle K, Carlson-Leuer K, Mehta J et al. Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia. Leuk Res 2012; 36: 394-396.
6. Meshinchi S, Alonzo TA, Stirewalt DL, Zwaan M, Zimmerman M, Reinhardt D et al. Clinical implications of FLT3 mutations in pediatric AML. Blood 2006; 108: 3654-3661. (Pubitemid 44864541)
7. Brown P, Meshinchi S, Levis M, Alonzo TA, Gerbing R, Lange B et al. Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition. Blood 2004; 104: 1841-1849. (Pubitemid 39202295)
8. Advani AS, Rodriguez C, Jin T, Jawde RA, Saber W, Baz R et al. Increased C-kit intensity is a poor prognostic factor for progression-free and overall survival in patients with newly diagnosed AML. Leuk Res 2008; 32: 913-918. (Pubitemid 351389542)
9. Advani AS, Tiu R, Saunthararajah Y, Maciejewski J, Copelan EA, Sobecks R et al. A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia. Leuk Res 2010; 34: 1622-1626.
10. Linger RM, Keating AK, Earp HS, Graham DK. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res 2008; 100: 35-83. (Pubitemid 351932179)
11. Graham DK, Salzberg DB, Kurtzberg J, Sather S, Matsushima GK, Keating AK et al. Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia. Clin Cancer Res. an official journal of the American Association for Cancer Research 2006; 12: 2662-2669.
12. Keating AK, Salzberg DB, Sather S, Liang X, Nickoloff S, Anwar A et al. Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase. Oncogene 2006; 25: 6092-6100. (Pubitemid 44562407)
13. Ling L, Kung HJ. Mitogenic signals and transforming potential of Nyk, a newly identified neural cell adhesion molecule-related receptor tyrosine kinase. Mol Cell Biol 1995; 15: 6582-6592.
14. Stitt TN, Conn G, Gore M, Lai C, Bruno J, Radziejewski C et al. The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell 1995; 80: 661-670.
15. Caberoy NB, Zhou Y, Li W. Tubby and tubby-like protein 1 are new MerTK ligands for phagocytosis. EMBO J 2010; 29: 3898-3910.
16. Caberoy NB, Alvarado G, Bigcas JL, Li W. Galectin-3 is a new MerTK-specific eat-me signal. J Cell Physiol 2012; 227: 401-407.
17. Avanzi GC, Gallicchio M, Cavalloni G, Gammaitoni L, Leone F, Rosina A et al. GAS6, the ligand of Axl and Rse receptors, is expressed in hematopoietic tissue but lacks mitogenic activity. Exp Hematol 1997; 25: 1219-1226. (Pubitemid 27508868)
18. Sather S, Kenyon KD, Lefkowitz JB, Liang X, Varnum BC, Henson PM et al. A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation. Blood 2007; 109: 1026-1033. (Pubitemid 46220648)
19. Hafizi S, Dahlback B. Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases. Cytokine Growth Factor Rev 2006; 17: 295-304. (Pubitemid 44038616)
20. Wang H, Chen S, Chen Y, Wang H, Wu H, Tang H et al. The role of Tyro 3 subfamily receptors in the regulation of hemostasis and megakaryocytopoiesis. Haematologica 2007; 92: 643-650. (Pubitemid 350144266)
21. Hong CC, Lay JD, Huang JS, Cheng AL, Tang JL, Lin MT et al. Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer Lett 2008; 268: 314-324.
22. Png KJ, Halberg N, Yoshida M, Tavazoie SF. A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature 2012; 481: 190-194.
23. Lunghi P, Tabilio A, Dall'Aglio PP, Ridolo E, Carlo-Stella C, Pelicci PG et al. Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts. Leukemia. official journal of the Leukemia Society of America, Leukemia Research Fund, UK 2003; 17: 1783-1793. (Pubitemid 37185254)
24. Xu Q, Simpson SE, Scialla TJ, Bagg A, Carroll M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 2003; 102: 972-980. (Pubitemid 36917792)
25. Guttridge KL, Luft JC, Dawson TL, Kozlowska E, Mahajan NP, Varnum B et al. Mer receptor tyrosine kinase signaling: prevention of apoptosis and alteration of cytoskeletal architecture without stimulation or proliferation. J Biol Chem 2002; 277: 24057-24066. (Pubitemid 34951918)
26. Odgerel T, Kikuchi J, Wada T, Shimizu R, Kano Y, Furukawa Y. MSK1 activation in acute myeloid leukemia cells with FLT3 mutations. Leukemia official journal of the Leukemia Society of America, Leukemia Research Fund, UK 2010; 24: 1087-1090.
27. Shankar DB, Cheng JC, Kinjo K, Federman N, Moore TB, Gill A et al. The role of CREB as a proto-oncogene in hematopoiesis and in acute myeloid leukemia. Cancer cell 2005; 7: 351-362. (Pubitemid 40544652)
28. Pigazzi M, Ricotti E, Germano G, Faggian D, Arico M, Basso G. cAMP response element binding protein (CREB) overexpression CREB has been described as critical for leukemia progression. Haematologica 2007; 92: 1435-1437. (Pubitemid 350144168)
29. Kinjo K, Sandoval S, Sakamoto KM, Shankar DB. The role of CREB as a protooncogene in hematopoiesis. Cell cycle 2005; 4: 1134-1135.
30. Muller-Tidow C, Klein HU, Hascher A, Isken F, Tickenbrock L, Thoennissen N et al. Profiling of histone H3 lysine 9 trimethylation levels predicts transcription factor activity and survival in acute myeloid leukemia. Blood 2010; 116: 3564-3571.
31. Bunting KD, Yu WM, Bradley HL, Haviernikova E, Kelly-Welch AE, Keegan AD et al. Increased numbers of committed myeloid progenitors but not primitive hematopoietic stem/progenitors in mice lacking STAT6 expression. J Leukoc Biol 2004; 76: 484-490. (Pubitemid 39006964)
32. Rogers AE, Le JP, Sather S, Pernu BM, Graham DK, Pierce AM et al. Mer receptor tyrosine kinase inhibition impedes glioblastoma multiforme migration and alters cellular morphology. Oncogene 2012; 31: 4171-4181.
33. Liu J, Yang C, Simpson C, Deryckere D, Van Deusen A, Miley MJ et al. Discovery of novel small molecule mer kinase inhibitors for the treatment of pediatric acute lymphoblastic leukemia. ACS Med Chem Lett 2012; 3: 129-134.
34. Keating AK, Kim GK, Jones AE, Donson AM, Ware K, Mulcahy JM et al. Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity. Mol Cancer Ther 2010; 9: 1298-1307.
35. Migdall-Wilson J, Bates C, Schlegel J, Brandao L, Linger RM, DeRyckere D et al. Prolonged exposure to a Mer ligand in leukemia: Gas6 favors expression of a partial Mer glycoform and reveals a novel role for Mer in the nucleus. PloS One 2012; 7: e31635.